Early high-dose Rosuvastatin for

Slides:



Advertisements
Similar presentations
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Advertisements

REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Total Occlusion Study of Canada (TOSCA-2) Trial
Nephrology Journal Club The SPRINT Trial Parker Gregg
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
European Society of Cardiology 2017 Clinical Trial Update I
Clinical Research at the VA
Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
VA Cooperative Studies Program Trial # 578
The IDEAL Study Reference
Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial Steven.
The Anglo Scandinavian Cardiac Outcomes Trial
The REAL-CAD Study in 13,054 Patients
ELIGIBILITY: MRC/BHF Heart Protection Study
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Scandinavian Simvastatin Survival Study (4S)
The ASSERT Study.
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Dr. Harvey White on behalf of the ACUITY investigators
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Hexabrix Key Clinical Review Mehran, 2009
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The Hypertension in the Very Elderly Trial (HYVET)
The results of the SHARP trial
Statins Evaluation in Coronary procedUres and REvascularization
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
European Heart Association Journal 2007 April
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
MK-0954 PN948 NOT APPROVED FOR USE (date)
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Impact of Platelet Reactivity Following Clopidogrel Administration
Erasmus MC, Thoraxcenter
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
Implications of Preoperative Thienopyridine Use
on behalf of the ACUITY investigators
What oral antiplatelet therapy would you choose?
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
The results of the SHARP trial
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) Study Anna Toso, MD on behalf of the PRATO-ACS investigators PRATO-ACS study

Principal investigator: Co-Investigators: Anna Toso Mario Leoncini Mauro Maioli Francesco Tropeano Francesco Bellandi Cardiology Division of Misericordia e Dolce Hospital, Prato, Italy Site management & monitoring: Hospital Ethics Committee Data management: Biostatistics: Centro Cardiopatici Toscani (non-profit organization) Simona Villani Section of Biostatistics and Clinical Epidemiology, Pavia University, Italy Financial support: no external financial support Trial Registration clinicaltrial.gov Identifier: NCT01185938 PRATO-ACS study

Contrast Nephropathy Role of Statins Uncertainties include: Anti-lipidemic and pleiotropic properties (anti-oxidant, anti-inflammatory, anti-thrombotic) may have a nephro-protective effect improving endothelial function and reducing oxidative stress. Uncertainties include: -type and dose -timing -target population PRATO-ACS study

for CI-AKI prevention in ACS patients Study Hypothesis On-admission high-dose statins for CI-AKI prevention in ACS patients Does early high-dose hydrophilic statin rosuvastatin -in addition to standard preventive measures (hydration and N-acetylcystein)- exert beneficial effects against CI-AKI in statin-naïve patients with NSTE-ACS scheduled for early invasive strategy? PRATO-ACS study

All consecutive statin-naïve NSTE-ACS patients Methods Inclusion criteria All consecutive statin-naïve NSTE-ACS patients admitted to CCU and scheduled for early invasive strategy Study period: July 2010-August 2012 PRATO-ACS study

Emergency (within 2 hrs) angiography Methods Exclusion criteria Emergency (within 2 hrs) angiography Acute renal failure or ESRD requiring dialysis Baseline serum creatinine ≥ 3 mg/dl Contraindications to statin treatment Contrast administration within the last 10 days Refusal to consent • PRATO-ACS study

Methods Study Design Statin-naive & Early Invasive Strategy NSTE-ACS patients R CCU-Admission Rosuvastatin 40 mg (LD) then 20 mg/day Hydration, N-Acetylcystein Controls ~ 24 H Coronary Angiography ± PCI Primary Endpoint: ↑ Cr ≥ 0.5 mg/dl or ≥ 25 % within 72 hrs of contrast exposure Contrast CI-AKI 72 H Sample size: assumed 18% CI-AKI in control and 50% reduction in treatment. With a 80% statistical power and 2-sided type 1 error of 5%; 15% drop out  ~ 540 pts

Additional End-points Methods Additional End-points 1. CI-AKI defined by other criteria: ↑ Cr ≥ 25 % or ≥ 0.5 mg/dl within 48 hrs ↑ Cr ≥ 0.3 mg/dl within 48 hrs ↑ Cr ≥ 0.5 mg/dl within 72 hrs ↑ Cr ≥ 0.3 mg/dl within 72 hrs ↓ eGFR ≥ 25% within 72 hrs PRATO-ACS study

Methods Additional End-points 2. CI-AKI in pre-specified subgroups Age < or  70 yrs Gender Diabetes mellitus Creatinine Clearance < / ≥ 60 ml/min LV-EF ≤ / > 45% CI-AKI Mehran risk score ≤ / > 5 Contrast volume administered ≤ / > 140 ml PCI procedure Clinical Risk Level (at least one of the following): Age ≥ 70 Diabetes mellitus Creatinine Clearance < 60 ml/min LV-EF ≤ 45%

Additional End-points Methods Additional End-points 3. Adverse Clinical Events (30 days): Acute renal failure requiring dialysis Persistent renal damage* All-causes mortality Myocardial infarction Stroke *↓ eGFR ≥ 25% within 1 month in CI-AKI pts PRATO-ACS study

Antiplatelet treatment: Methods Additional Protocol Details Antiplatelet treatment: ASA (300 mg LD, 100 mg/day MD) Clopidogrel (600 mg LD, 150 mg/day→ discharge) • Hydration i.v.12 hrs pre and post contrast medium (isotonic saline 1 ml/kg/h or 0.5 ml/kg/h if LV-EF < 40% ) Oral N-Acetylcystein 24 hrs pre and post contrast medium (2400 mg/day) Nonionic, dimeric iso-osmolar contrast medium (Iodixanol) & Power injector (ACIST) At discharge: Clopidogrel 75 mg/day, ASA 100 mg/day & Rosuvastatin group Rosuvastatin 20 mg/day (10 mg/day if CrCL< 30 ml/min) Controls Atorvastatin 40 mg/day Discharge

Statin-naive & Early Invasive Strategy NSTE-ACS patients Study Flow Statin-naive & Early Invasive Strategy NSTE-ACS patients Randomized n = 543 Rosuvastatin n = 271 Excluded = 19 no angiography = 9 no 72 hrs creatinine = 10 CI-AKI analysis n = 252 Controls n = 272 Excluded = 20 no angiography = 8 no 72 hrs creatinine = 12 CI-AKI analysis n = 252

Baseline Characteristics Clinical and Demographic Rosuvastatin 66.2 ± 12.4 46.4 34 26.2 ± 3.7 Control 66.1 ± 13.5 44.8 34 26.6 ± 4.4 p value 0.91 0.72 0.93 0.35 Age Age ≥ 70 years.% Female, % Body Mass Index Clinical presentation, % NSTE-MI Unstable angina 92.4 7.5 92.1 7.9 >0.90 Risk factors, % Hypertension Diabetes mellitus Creatinine clearance < 60ml/min Previous MI Previous PCI or CABG Baseline LV EF (%) EF < 45% High Clinical Risk Level, % 56.7 19.8 41.7 9.5 11.9 50 ± 9 33.3 71.4 54.8 22.6 41.7 5.9 7.1 50 ± 9 33.7 67.1 0.65 0.45 >0.90 0.13 0.07 0.93 0.29

Baseline Characteristics Biochemical Rosuvastatin 0.95 ± 0.27 69.9 ± 24.4 14.1 ± 1.6 0.43 (0.21-1.18) 2.3 ± 5.1 19.2 ± 3 5.2 135.2 ± 38.6 40.2 ±13.7 119.7 ± 62.8 131.7 ± 50.1 Control 0.96 ± 0.28 69.3 ± 24.9 14.1 ± 1.6 0.52 (0.20-1.28) 2.5 ± 7.0 23.1 ± 48.8 135.8 ± 42.7 42.3 ± 13.3 118 ± 73 137.3 ± 53.4 p value 0.89 0.81 0.77 0.57 0.41 0.34 0.85 0.08 0.78 0.23 Serum creatinine (mg/dl) Creatinine Clearance (ml/min) Haemoglobin (mg/dl) hs-CRP (mg/dl) cTn-I (ng/ml) CK-MB (ng/ml) LDL - Cholesterol (mg/dl) HDL - Cholesterol (mg/dl) Triglycerides (mg/dl) Glycaemia (mg/dl)

Procedural data Rosuvastatin 22.5 (14 – 43) 48.8 149.7 ± 86.8 46.4 21.4 10.7 67.9 Control 23 (15 – 45.5) 47.6 138.2 ± 77.8 40.1 23.8 11.9 64.3 p value 0.79 0.78 0.14 0.15 0.70 Randomization-to-Contrast time (hrs) Multivessel disease, % Contrast volume (ml) Contrast volume >140 ml Therapeutic strategy, % Medical treatment CABG PCI PCI data Multivessel PCI Contrast volume (ml) Contrast volume >140 ml, % CI-AKI Mehran risk score, median (IQR) ≤ 5, % >5, % 33.9 183 ± 80 64.9 3 (1 – 6) 74.2 25.8 28.3 172 ± 72 59.8 2 (1 – 5) 76.6 23.4 0.21 0.18 0.20 0.36

CI-AKI Primary Endpoint ( 0.5 or  25% within 72 hrs) ORcrude (95% CI): 0.41 (0.22 - 0.74) ORadjusted (95% CI): 0.38 (0.20 – 0.71) NNT = 12 *Adjusted for: Sex, Age, Diabetes, Hypertension, LDL-cholesterol, Creatinine Clearance, LV-EF, Contrast Volume, CI-AKI Risk Score PRATO-ACS study

Additional Endpoints: 1.Different CI-AKI criteria PRATO-ACS study

Additional Endpoints: 2.Pre-specified Subgroups

3. Adverse Clinical Events (30 days) Additional Endpoints: 3. Adverse Clinical Events (30 days) PRATO-ACS study

Conclusions-1 In statin-naïve patients with NSTE-ACS scheduled for early invasive strategy on-admission high-dose rosuvastatin: •exerts additional preventive effects against CI-AKI (w/ hydration & N-Acetylcystein); •is associated to better short-term clinical outcome. PRATO-ACS study

This study suggests that in NSTE-ACS Conclusions-2 This study suggests that in NSTE-ACS patients scheduled for early invasive strategy high-dose statins should be given on admission and in any case must precede the angiographic procedure in order to reduce renal complications after contrast medium administration. PRATO-ACS study

Thank you for your attention!